Multiple loci identified in a genome-wide association study of prostate cancer

Nature Genetics

Volumn 40, Issue 3, 2008, Pages 310-315

  Thomas, Gilles ^a   Jacobs, Kevin B ^b   Yeager, Meredith ^a,c   Kraft, Peter ^d   Wacholder, Sholom ^a   Orr, Nick ^a   Yu, Kai ^a   Chatterjee, Nilanjan ^a   Welch, Robert ^a,c   Hutchinson, Amy ^a,c   Crenshaw, Andrew ^a,c   Cancel Tassin, Geraldine ^e   Staats, Brian J ^a,c   Wang, Zhaoming ^a,c   Gonzalez Bosquet, Jesus ^a   Fang, Jun ^a   Deng, Xiang ^a,c   Berndt, Sonja I ^a   Calle, Eugenia E ^f   Feigelson, Heather Spencer ^f   Thun, Michael J ^f   Rodriguez, Carmen ^f   Albanes, Demetrius ^a   Virtamo, Jarmo ^g   Weinstein, Stephanie ^a   Schumacher, Fredrick R ^d   Giovannucci, Edward ^d   Willett, Walter C ^d   Cussenot, Olivier ^e   Valeri, Antoine ^e   Andriole, Gerald L ^h   Crawford, E David ⁱ   Tucker, Margaret ^a   Gerhard, Daniela S ^a   Fraumeni Jr , Joseph F ^a   Hoover, Robert ^a   Hayes, Richard B ^a   Hunter, David J ^a,d   Chanock, Stephen J ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b Bioinformed Consulting Services   (United States)

^c SAIC FREDERICK INC   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f AMERICAN CANCER SOCIETY   (United States)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA MICROSEMINOPROTEIN; BIOLOGICAL MARKER;

APOPTOSIS; ARTICLE; CDH13 GENE; CHROMOSOME 10; CHROMOSOME 11; CHROMOSOME 7; CHROMOSOME 8Q; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CPNE3 GENE; CTBP2 GENE; ENDOMETRIUM CANCER; GENE; GENE FUSION; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; HIGH RISK PATIENT; HNF1B GENE; HUMAN; IL16 GENE; MAJOR CLINICAL STUDY; MALE; MSMB GENE; PRIORITY JOURNAL; PROSTATE CANCER; REPRESSOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SUZ12 GENE;

CADHERINS; CASE-CONTROL STUDIES; CHROMOSOME MAPPING; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; INTERLEUKIN-16; LINKAGE (GENETICS); LINKAGE DISEQUILIBRIUM; MALE; PHOSPHOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; QUANTITATIVE TRAIT LOCI;

EID: 39749118602     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.91     Document Type: Article

References (30)

1. Crawford, E.D. Epidemiology of prostate cancer. Urology 62, 3-12 (2003).
2. Steinberg, G.D., Carter, B.S., Beaty, T.H., Childs, B. & Walsh, P.C. Family history and the risk of prostate cancer. Prostate 17, 337-347 (1990).
3. Amundadottir, L.T. et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38, 652-658 (2006).
4. Freedman, M.L. et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc. Natl. Acad. Sci. USA 103, 14068-14073 (2006).
5. Gudmundsson, J. et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39, 631-637 (2007).
6. Haiman, C.A. et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 39, 638-644 (2007).
7. Yeager, M. et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39, 645-649 (2007).
8. Gudmundsson, J. et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 39, 977-983 (2007).
9. Schaid, D.J. The complex genetic epidemiology of prostate cancer. Hum. Mol. Genet. 13 Spec No 1, R103-21 (2004).
10. Skol, A.D., Scott, L.J., Abecasis, G.R. & Boehnke, M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet. 38, 209-213 (2006).
11. Frazer, K.A. et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 449, 851-861 (2007).
12. Prorok, P.C. et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control. Clin. Trials 21, 273S-309S (2000).
13. Gohagan, J.K., Prorok, P.C., Hayes, R.B. & Kramer, B.S. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control. Clin. Trials 21, 251S-272S (2000).
14. Calle, E.E. et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 94, 2490-2501 (2002).
15. Chen, Y.C. et al. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res. 65, 11771-11778 (2005).
16. Valeri, A. et al. Segregation analysis of prostate cancer in France: evidence for autosomal dominant inheritance and residual brother-brother dependence. Ann. Hum. Genet. 67, 125-137 (2003).
17. The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann. Epidemiol. 4, 1-10 (1994).
18. Chanock, S.J. et al. Replicating genotype-phenotype associations. Nature 447, 655-660 (2007).
19. Zanke, B.W. et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet. 39, 989-994 (2007).
20. Easton, D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087-1093 (2007).
21. Janssen, J.W. et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood 95, 2691-2698 (2000).
22. Buckland, P.R. et al. Strong bias in the location of functional promoter polymorphisms. Hum. Mutat. 26, 214-223 (2005).
23. Nam, R.K. et al. A novel serum marker, total prostate secretory protein of 94 aminoacids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J. Urol. 175, 1291-1297 (2006).
24. Reeves, J.R., Dulude, H., Panchal, C., Daigneault, L. & Ramnani, D.M. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin. Cancer Res. 12, 6018-6022 (2006).
25. Beke, L., Nuytten, M., Van Eynde, A., Beullens, M. & Bollen, M. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 26, 4590-4595 (2007).
26. Paliwal, S. et al. The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor. Cancer Res. 67, 9322-9329 (2007).
27. Koontz, J.I. et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc. Natl. Acad. Sci. USA 98, 6348-6353 (2001).
28. Dixon, A.L. et al. A genome-wide association study of global gene expression. Nat. Genet. 39, 1202-1207 (2007).
29. Wang, X.D. et al. Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis. Differentiation 75, 219-234 (2007).
30. Gimm, O. et al. Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas. J. Clin. Endocrinol. Metab. 86, 1801-1805 (2001).